Drug intelligence / Profile preview

AL-121

Development stage: Preclinical
Lead developer: ALPS Biotech
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules

Overview

AL-121 is a plant-derived botanical drug candidate under preclinical development by ALPS Biotech for the treatment of COVID-19 and post-viral infection sequelae (long COVID). It targets angiotensin-converting enzyme 2 (ACE-2), a key receptor utilized by SARS-CoV-2 for host cell entry, to inhibit viral infection and replication. Preclinical in vivo studies in mouse models have demonstrated its potential efficacy as an anti-viral therapeutic.

Targets

ACE2 (Angiotensin-converting enzyme 2)

Beyond the preview

Go deeper on AL-121.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AL-121.